肝硬化退伍军人中丙型肝炎病毒清除后肝脏硬度测量与肝细胞癌风险预测
该回顾性队列研究纳入1850例丙型肝炎肝硬化并获持续病毒学应答的退伍军人,随访5099人年。肝脏硬度每增加1 kPa,肝细胞癌风险增加3%(aHR 1.03)。肝脏硬度<5 kPa且无糖尿病者调整年肝细胞癌风险<0.4%,可考虑停止监测。
要点
- 丙肝肝硬化获持续病毒学应答后,肝脏硬度测量可分层肝细胞癌风险。
- 肝脏硬度每增加1 kPa,肝细胞癌风险增加3%(aHR 1.03,95%CI 1.01-1.04)。
- 肝脏硬度<5 kPa且无糖尿病者年肝细胞癌风险<0.4%,可停止监测。
核心结论
- 肝脏硬度测量可在多个临界值水平预测丙肝肝硬化获持续病毒学应答后的肝细胞癌发生率,并提供单一检测预测门脉高压相关并发症和肝细胞癌。
- 肝脏硬度<5 kPa且无糖尿病者肝细胞癌风险低,可停止监测。
研究设计与样本
- 回顾性队列研究,从退伍军人健康管理局识别1850例丙型肝炎肝硬化并获持续病毒学应答的参与者,随访5099人年,从持续病毒学应答后弹性成像至死亡、肝细胞癌或研究结束。
主要发现
- 肝脏硬度每增加1 kPa,肝细胞癌风险增加3%(aHR 1.03,95%CI 1.01-1.04;P<.001)。
- 距持续病毒学应答年数增加,肝细胞癌风险降低(aHR 0.79;95%CI 0.70-0.90;P=.0003)。
- 调整年肝细胞癌风险:肝脏硬度<10 kPa为2.03%,10-14.9 kPa为2.48%(aHR 1.71;95%CI 1.01-2.88;P=.046),15-19.9 kPa为3.22%(aHR 1.59;95%CI 0.78-3.20;P=.20),20-24.9 kPa为5.07%(aHR 2.55;95%CI 1.30-5.01;P=.01),≥25 kPa为5.44%(aHR 3.03;95%CI 1.74-5.26;P<.0001)。
- 肝脏硬度<5 kPa且无糖尿病者调整年肝细胞癌风险<0.4%。
关键数值与推荐
- 肝脏硬度每增加1 kPa,肝细胞癌风险增加3%(aHR 1.03,95%CI 1.01-1.04;P<.001)。
- 肝脏硬度10-14.9 kPa组aHR 1.71(95%CI 1.01-2.88;P=.046),15-19.9 kPa组aHR 1.59(95%CI 0.78-3.20;P=.20),20-24.9 kPa组aHR 2.55(95%CI 1.30-5.01;P=.01),≥25 kPa组aHR 3.03(95%CI 1.74-5.26;P<.0001)。
- 肝脏硬度<5 kPa且无糖尿病者调整年肝细胞癌风险<0.4%。
临床怎么用
- 作者认为,对丙肝肝硬化获持续病毒学应答者,肝脏硬度测量可预测肝细胞癌风险。
- 作者认为,肝脏硬度<5 kPa且无糖尿病者肝细胞癌风险低,可停止监测。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Patients with cirrhosis secondary to chronic hepatitis C virus (HCV) are at risk for hepatocellular carcinoma (HCC) despite a sustained virological response (SVR). We examined whether post-SVR liver stiffness measurement (LSM) could be used to stratify HCC risk. METHODS: This was a retrospective cohort study of 1850 participants identified from the Veterans Health Administration, with HCV cirrhosis and SVR, followed up over 5099 person-years, from the time of post-SVR elastography until death, HCC, or the end of the study. RESULTS: The risk of HCC increased by 3% with every 1-kPa increase in LSM (adjusted hazard ratio [aHR], 1.03, 95% confidence interval [CI], 1.01-1.04; P < .001) and decreased with the number of years from SVR (aHR, 0.79; 95% CI, 0.70-0.90; P = .0003). The adjusted annual risk of HCC was 2.03% among participants with post-SVR LSM <10 kPa, 2.48% in LSM 10-14.9 kPa (aHR, 1.71; 95% CI, 1.01-2.88; P = .046), 3.22% for LSM 15-19.9 kPa (aHR, 1.59; 95% CI, 0.78-3.20; P = .20), 5.07% among LSM 20-24.9 kPa (aHR, 2.55; 95% CI, 1.30-5.01; P = .01), and 5.44% in LSM ≥25 kPa (aHR, 3.03; 95% CI, 1.74-5.26; P < .0001). The adjusted annual risk of HCC was < 0.4% in participants with LSM <5 kPa and without diabetes mellitus. CONCLUSIONS: LSM predicts rates of HCC in patients with HCV cirrhosis after SVR at multiple cutoff levels and offers a single test to predict portal hypertension-related complications and HCC. Patients with LSM <5 kPa in the absence of diabetes mellitus had a low risk of HCC in which surveillance could be discontinued.
引用
- John BV, Dang Y, Kaplan DE, et al. Liver Stiffness Measurement and Risk Prediction of Hepatocellular Carcinoma After HCV Eradication in Veterans With Cirrhosis. Clin Gastroenterol Hepatol. 2023. PMID: 38061410. doi:10.1016/j.cgh.2023.11.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。